Walgreens Boots Alliance Reports Fiscal 2019 Third Quarter Results
Third quarter highlights, year-over-year Sales increased 0.7 percent to $34.6 billion Operating income decreased 24.7 percent to $1.2 billion; Adjusted…
Pharmaceuticals, Biotechnology and Life Sciences
Third quarter highlights, year-over-year Sales increased 0.7 percent to $34.6 billion Operating income decreased 24.7 percent to $1.2 billion; Adjusted…
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Coronary Artery Disease” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the…
PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today…
Company Will Prioritize Continued Development of Mirvetuximab Soravtansine and a Select Portfolio of Earlier-Stage Candidates Cash Runway Extended Through Readout…
STAMFORD, Conn.–(BUSINESS WIRE)–SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases…
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Hepatitis B” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the Hepatitis…
Takeda’s founding mission to serve patients, wherever they are, drives its increased commitments to disease prevention, capacity building, and access to healthcare in developing and emerging countries, in partnership with the global community.
— Dr. Torsten Matthias appointed CEO, scientific founder Prof. Dr. Armin Giese joins as CSO —
— SERY technology in-licensed from Max-Planck Innovation GmbH to design next-generation candidate portfolio —
Agreement targets the development of a cross-reactive vaccine to protect against the most virulent enteroviruses, including enterovirus 71 (EV71)
Morphic announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a price to the public of $15.00 per share